Module 15 · 40 min

Controversies, Pipeline & Frontier

What's in phase II/III right now — and what 2027 will probably look like.

CoreClinicalAdvanced

Core topics

What's covered

Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.

Learning objectives

By the end of this module you will be able to

L01Name three pipeline molecules expected to file by 2027.
L02Articulate the 'muscle preservation during weight loss' problem and current peptide solutions.

Expected takeaways

What you should walk away believing

Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.

Takeaway mastery

0 / 1 · 0%

A takeaway counts as mastered when you score ≥80% on its self-check.

Lesson · Core emphasis

What this means for you

Patient summary

The wave that started with Ozempic isn't slowing down — expect new options every year, including oral pills and combinations that preserve muscle while losing fat.

Clinician summary

Track: retatrutide, orforglipron, CagriSema, bimagrumab, taldefgrobep alfa, survodutide, and the post-MASH approval landscape (resmetirom is a small molecule; semaglutide/tirzepatide MASH RCTs are reading out).

Evidence-graded claims